Apogee Therapeutics Banner Image

Apogee Therapeutics

  • Ticker apge
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
  • 201-500 Employees
  • Based in Waltham, MA
Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-establishedMore mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care.
Apogee Therapeutics

Most Recent Annual Report

Apogee Therapeutics
MOST RECENT 2023 Annual Report

Apogee Therapeutics does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!